Clinical Trial Update: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of futibatinib and pembrolizumab for advanced or metastatic urothelial carcinoma was terminated, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Futibatinib (futibatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Advanced and Metastatic Urothelial Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-12-31